Search | IOVS | ARVO Journals

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Evaluation of Reproducibility and Uniformity of PRINT Implant Manufacturing

Melissa Sandahl; Dustin Melton; Janet Tully; Mari Yang; Andres Garcia; Leo Trevino; Stuart Williams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5671. doi:

ARVO Annual Meeting Abstract June 2017

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

Gary Owens; Melissa Sandahl; Janet Tully; Jennifer Haley; Kwadwo Caesar; Stuart Williams; Rozemarijn S Verhoeven; Andres Garcia; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):409. doi:

ARVO Annual Meeting Abstract June 2017

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Sanjib Das; Kristie Hamby; Melissa Hernandez; Glenwood G Gum; Benjamin R Yerxa; Tomas Navratil

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1072. doi:

ARVO Annual Meeting Abstract June 2017

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

Stuart Williams; Rozemarijn S Verhoeven; Dustin Melton; Janet Tully; Sanjib Das; RiLee Robeson; Andres Garcia; Mari Yang; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4457. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Paul Miller; Jacqueline Miller; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4013. doi:

ARVO Annual Meeting Abstract September 2016

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Rozemarijn S Verhoeven; RiLee Robeson; Andres Garcia; Brian C Gilger; David Culp; Craig B Struble; Lee Hamm; Thomas Grizzle; Tomas Navratil; Rhett M Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5711. doi:

ARVO Annual Meeting Abstract September 2016

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Tomas Navratil; Jessie Delgado; Andres Garcia; Gretchen Willard; Andrew Corson; Rozemarijn S Verhoeven; Leo Trevino; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3021. doi:

ARVO Annual Meeting Abstract September 2016

Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

Gary Owens; Melissa Sandahl; Melissa Hernandez; Andres Garcia; Stuart Williams; Tomas Navratil; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):527. doi:

ARVO Annual Meeting Abstract June 2015

The Aseptic Fabrication of ENV515 (Travoprost) Intracameral Implants

Leo Trevino; Michael Hunter; Sanjib Das; Tyler Pegoraro; Tyler Massey; Andres Garcia; Janet Tully; Kristie Hamby; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4158. doi:

ARVO Annual Meeting Abstract June 2015

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Tomas Navratil; Andres Garcia; Rozemarijn S Verhoeven; Leo Trevino; Brian C Gilger; Steven L Mansberger; Donald L Budenz; Iqbal Ike K. Ahmed; Richard A. Lewis; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5706. doi:

ARVO Annual Meeting Abstract June 2015

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

Andres Garcia; Rozemarijn S Verhoeven; Tyler Pegoraro; Jeremy Hansen; Jinny Conley; Rilee Robeson; Brian C Gilger; Tomas Navratil; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5897. doi:

ARVO Annual Meeting Abstract April 2014

Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action

Tomas Navratil; Andres Garcia; Janet Tully; Benjamin Maynor; Iqbal Ike K Ahmed; Donald L Budenz; Richard A Lewis; Steven L Mansberger; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3548. doi:

ARVO Annual Meeting Abstract April 2014

Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology

Ayush Verma; Jeff Kindig; Kyle Sebastian; Janet Tully; Andres Garcia; RiLee Robeson; Benjamin Maynor; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):476. doi:

ARVO Annual Meeting Abstract April 2014

Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber

Andres Garcia; Janet Tully; Sanjib Das; Tyler Pegoraro; Leo Trevino; Benjamin Maynor; Tomas Navratil; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5268. doi:

ARVO Annual Meeting Abstract April 2014

Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics

Benjamin Maynor; Andres Garcia; Janet Tully; Gary Owens; RiLee Robeson; Tomas Navratil; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5269. doi:

ARVO Annual Meeting Abstract April 2014

Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model

Leo Trevino; Tomas Navratil; RiLee Robeson; Andres Garcia; Janet Tully; Michael Hunter; Daria Stoltz; Benjamin Maynor; Brian C Gilger; Benjamin R Yerxa

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5270. doi:

ARVO Annual Meeting Abstract June 2013

Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone

Andres Garcia; Janet Tully; Benjamin Maynor; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1079. doi:

ARVO Annual Meeting Abstract June 2013

Application of PRINT Microparticle and Nanoparticle Technology Toward Preparation of Ophthalmic Suspension Formulations with Improved Tolerability and Efficacy

Benjamin Maynor; Andres Garcia; Janet Tully; Benjamin Yerxa

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1091. doi:

NARROW

Content Type

Journal

Article Type

Specify Date Range

Evaluation of Reproducibility and Uniformity of PRINT Implant Manufacturing

Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants

A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs

Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

The Aseptic Fabrication of ENV515 (Travoprost) Intracameral Implants

Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action

Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology

Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber

Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics

Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model

Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone

Application of PRINT Microparticle and Nanoparticle Technology Toward Preparation of Ophthalmic Suspension Formulations with Improved Tolerability and Efficacy

To View More...

You must be signed into an individual account to use this feature.